Data published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA
Plasma PK data indicate the total and maximal exposure to triamcinolone acetonide (TA) was approximately two-thirds lower in patients treated with ZILRETTA compared to triamcinolone acetonide in crystalline suspension (TAcs)
Registration trial in patients with shoulder OA expected to begin later this year
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.